Roche Diagnostics Australia is pleased to announce an Organisational Sustaining Membership with the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).
Diagnostics play a critical role in the diagnosis and monitoring of infectious diseases, and as a leader in this area, we are excited and honoured to partner with ASHM. The COVID-19 pandemic has adversely impacted many initiatives in the fight against Blood Borne Viruses and Sexually Transmitted Infections. However, with a renewed effort, we can achieve our national strategy targets.
We look forward to collaborating with ASHM and fellow partner organisations in order to contribute to our shared goal of improving the lives of people living with HIV, viral hepatitis, sexual and reproductive health issues, and related diseases.
The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) was formed in the early 1990s and has grown to become a peak body representing health professionals working on HIV, viral hepatitis, other BBVs, and sexually transmissible infections in Australia and New Zealand.
ASHM is a professional, non-profit, member-based group with over 5000 active affiliate members (individuals) and more than 60 organisational members. ASHM supports its members, sector partners and collaborators to generate knowledge and action in clinical management and research, education, policy and advocacy in Australasia and internationally.
ASHM’s vision for reconciliation is for the Aboriginal and Torres Strait Islander peoples to experience equity, dignity, and respect in all aspects of life. The HTLV1 virus is shockingly prevalent amongst indigenous Australian communities, present in up to 50% of aboriginal communities across the top end. Like HIV, it is transmitted through a similar means for example, sexual contact and breastfeeding. Therefore, Aboriginal and Torres Strait Islander people's representation in research, policy and health education is an ongoing goal for both ASHM and Roche Diagnostics Australia.
Roche's organisational membership status will help to further scientific study and progress toward the elimination of these infectious diseases by supporting the organisation to bring about a number of industry and world leading events held in Australia throughout the year. The partnership is one of our commitments to providing better health outcomes for everyone in Australia.
For 30 years, ASHM has worked to bring together delegates from Australia, New Zealand, Asia, and the Pacific with the vision of virtual elimination of HIV, viral hepatitis, other BBVs and significant reduction of sexually transmissible infections.
Roche Diagnostics Australia has partnered with ASHM in its mission to provide leadership in the field of HIV, viral hepatitis, other BBVs and sexually transmissible infections through collaboration, facilitation, direct action, and workforce capacity building.
The ASHM Inaugural COVID-19 Conference Day held in July is a one-day conference, bringing together an array of experts from the disciplines of basic science, clinical care, epidemiology, and social science.
The Australasian Viral Hepatitis Conference provides key sector partners a platform for the dissemination and presentation of new and innovative research findings and better management across the Australasian viral hepatitis sector.
The forum helps to support the health workforce, government, and community to work towards the elimination of hepatitis B and hepatitis C to support the communities living with these conditions in Australia, New Zealand and the Asia and Pacific regions.
For 30 years the Joint Australasian HIV&AIDS Conference, the leading HIV conference in Australasia, has brought together delegates from Australia, New Zealand, Asia, and the Pacific.
This year the Australasian Sexual health Conference will runs in conjunction with the HIV&AIDS conference, is delivered in collaboration with The Australasian Sexual and Reproductive Health Alliance (ASRHA)
